Quest Diagnostics IncorporatedDGX
NYSE • Healthcare
$190.59
P/E
21.71
PEG
0.02
FCF Yield
—
Rev Growth YoY
+1178.0% YoY
Gross Margin
3332.0%
Health Score
5/10
D/E Ratio
0.82
Confidence
LOW
Business Snapshot
Quest Diagnostics is one of the largest clinical laboratory testing companies in the United States, providing diagnostic information services to physicians, hospitals, health plans, and patients. The company operates across a broad spectrum of routine and esoteric testing, serving as a critical part of the healthcare information infrastructure. Based on available valuation ratios and price data, DGX appears to be a large-cap healthcare name, though a precise market capitalisation figure is not available in this dataset.
Financial Health
Score: 5/10
The balance sheet presents a mixed picture. Debt/equity stands at 0.82x, which is manageable and not a near-term solvency concern...
Risk Assessment
- DATA INTEGRITY: Revenue growth of 1,178% YoY, gross margins of 3,332%, and net margins of 899% are almost certainly data artefacts, making fundamental analysis unreliable without verification from primary filings.
- LIQUIDITY: Current ratio of 1.04x provides minimal buffer above 1.0x, leaving little room for operational or working capital stress.
- CASH FLOW OPACITY: Free cash flow is unavailable, preventing assessment of true earnings quality or capital return sustainability.
- TECHNICALS: A confirmed death cross (50-day MA crossing below 200-day MA) and bearish MACD signal suggest negative price momentum, with the stock sitting below both key moving averages and 10.7% off its 52-week high of $213.50.
- VALUATION ANCHORING: No DCF fair value estimate is available and DCF confidence is rated low, leaving no independent check on whether the current price of $190.59 reflects intrinsic value.
---...
**Score: 5/10** The balance sheet presents a mixed picture. Debt/equity stands at 0.82x, which is manageable and not a near-term solvency concern. The current ratio of 1.04x indicates the company can just cover its short-term obligations, but with minimal cushion — any liquidity stress could be uncomfortable. Critically, free cash flow data is unavailable, which limits a full assessment of earnings quality and the company's ability to fund dividends, buybacks, or debt reduction from operations. The reported gross margin figure of 3,332% and net margin of 899% appear anomalous and likely reflect a data normalisation or reporting artefact rather than genuine operating economics, and therefore cannot be relied upon for margin health conclusions. ---
- **DATA INTEGRITY:** Revenue growth of 1,178% YoY, gross margins of 3,332%, and net margins of 899% are almost certainly data artefacts, making fundamental analysis unreliable without verification from primary filings. - **LIQUIDITY:** Current ratio of 1.04x provides minimal buffer above 1.0x, leaving little room for operational or working capital stress. - **CASH FLOW OPACITY:** Free cash flow is unavailable, preventing assessment of true earnings quality or capital return sustainability. - **TECHNICALS:** A confirmed death cross (50-day MA crossing below 200-day MA) and bearish MACD signal suggest negative price momentum, with the stock sitting below both key moving averages and 10.7% off its 52-week high of $213.50. - **VALUATION ANCHORING:** No DCF fair value estimate is available and DCF confidence is rated low, leaving no independent check on whether the current price of $190.59 reflects intrinsic value. ---
Unlock the full AI report
Full 8-section analysis includes:
Metric deep-dives